Why painful arthritis can return stronger after cancer treatment

Researchers at The University of Texas MD Anderson Cancer Center have found evidence that arthritis triggered by certain cancer immunotherapies behaves like a disease driven by immune memory. Rather than launching an entirely new inflammatory response during each flare, the immune system appears to reactivate cells involved in earlier episodes.

The discovery could eventually help doctors identify patients at risk of recurring arthritis and develop treatments that control joint inflammation without interfering with the immune system's ability to fight cancer.

The study, published in Cancer Immunology Research, was led by scientists at UT MD Anderson and Yale University. The research team included Roza I. Nurieva, Ph.D., professor of Immunology; Synat Keam, Ph.D., a postdoctoral fellow in the Nurieva Laboratory; and Yuanteng Jeff Li, M.D., assistant professor of General Internal Medicine. Sang Taek Kim, M.D., Ph.D., an assistant professor at Yale University, also co-led the investigation.

"Cancer immunotherapy works by creating a lasting immune response against tumors, but that same persistence may also contribute to recurring inflammatory side effects that can be debilitating for patients," Nurieva said. "By identifying the immune cells that drive recurrent arthritis, we can inform treatment strategies that reduce the risk of future flares while preserving the therapy's effectiveness against cancer."

Why Cancer Immunotherapy Can Trigger Painful Arthritis

Immune checkpoint inhibitors are widely used cancer treatments that help the body's natural defenses recognize and attack tumor cells. These drugs are a form of immunotherapy that works by removing some of the molecular restraints that normally keep immune activity under control.

Although this approach can help the immune system destroy cancer cells, it can sometimes cause immune cells to attack healthy tissues as well. When the joints become targets, patients may develop inflammatory arthritis, a condition that causes pain, swelling, and inflammation.

For some patients, the problem does not disappear after the first episode. Approximately 20% to 50% of patients who develop this complication experience repeated arthritis flares, and symptoms can persist for months or even years after immunotherapy ends.

These recurring episodes are often more intense than the initial attack, raising an important question: Why does the immune system continue to produce inflammation, and why can its response become increasingly aggressive?

Scientists Discover Immune Cells That Remember Previous Attacks

To investigate, the researchers examined fluid taken from the joints of six patients during both their first arthritis episode and a later recurrence.

Their analysis revealed two distinct populations of immune cells that appeared during both flares. One consisted of inflammatory CD8 T cells, while the other was a specialized group of CD4 T cells expressing two markers known as PD-1 and CXCL13.

T cells are immune cells that help coordinate the body's defenses and respond to potential threats. Some can also persist after an initial immune response, allowing the immune system to react more quickly when it encounters a familiar target.

The presence of the same immune cell populations during separate arthritis attacks suggests that recurring inflammation may arise from cells already involved in the earlier episode. Instead of starting from scratch, the immune system appears to reactivate an established inflammatory response.

This immune memory mechanism could help explain why arthritis can repeatedly return even after cancer treatment has stopped.

Why Arthritis Flares May Become More Severe

The researchers also found that the recurring immune cells appeared more active during subsequent arthritis episodes. They produced increased amounts of inflammatory signaling molecules, which immune cells use to communicate and influence one another.

Another finding was particularly unexpected. Regulatory T cells, which normally act as a braking system to prevent excessive immune activity, also began producing inflammatory molecules during recurring flares.

This suggests that some of the cells responsible for keeping inflammation under control may instead contribute to it, potentially weakening the body's ability to shut down the response.

The researchers also identified extensive communication networks connecting inflammatory cells within affected joints. These signaling networks became more pronounced during the second arthritis episode.

Together, the findings suggest that recurring flares involve a coordinated and increasingly active inflammatory environment, rather than just a handful of immune cells acting independently.

Could Immune Memory Help Predict Future Arthritis Flares?

Despite growing recognition of inflammatory arthritis as a complication of cancer immunotherapy, scientists still do not fully understand why it affects certain patients while others never develop the condition.

The newly identified immune cell populations could provide an important starting point. Future studies may determine whether these cells can serve as biomarkers, meaning measurable biological indicators that help doctors recognize patients who are more likely to experience recurring arthritis.

Understanding which immune cells sustain the inflammation could also guide the development of more precise treatments. Ideally, such therapies would prevent or reduce painful arthritis flares while leaving the beneficial cancer-fighting effects of immunotherapy intact.

Because the investigation examined samples from only six patients, additional research will be needed to confirm the findings and establish whether the identified immune cells can reliably predict future episodes.

Still, the results offer a promising explanation for a difficult complication of cancer treatment: an immune system trained to remember and fight tumors may also retain inflammatory responses that continue to harm the joints.

This work received support from the Wilkes Family Melanoma Autoimmune Research Fund, the National Institutes of Health, the Advanced Technology Genomics Core Facility, the Rheumatology Research Foundation Fund, the National Cancer Institute (NCI), the Andrew Sabin Family Fellowships, the Gateway for Cancer Research, the U.S. Department of Defense, the Kidney Cancer Association, the V Foundation for Cancer Research, the Finneran Family Endowment in Translational Research, philanthropic donations from the family of Mike and Mary Allen, and institutional funding from UT MD Anderson.